-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $330

Benzinga·11/02/2026 13:24:44
Listen to the news
RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $280 to $330.